Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BRII-196 and BRII-198 in healthy volunteers
NCT04691180Phase 1Completed
- Sponsor
- Brii Biosciences
- Start
- Jan 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of amubarvimab and romlusevimab in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Brii Biosciences. Primary endpoints: Incidence of adverse events at 24 weeks and Proportion of subjects with Serious Adverse Events at 24 weeks. Started Jan 2021; status: completed.
02
Drugs
amubarvimabromlusevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04691180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691180.